Bellerophon Therapeutics Inc., of Hampton, N.J., expanded its license agreement with Dublin-based Mallinckrodt plc division Ino Therapeutics LLC, allowing Bellerophon to develop Inopulse, a drug-device combination system designed to reduce pulmonary hypertension (PH), for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic PH, PH associated with sarcoidosis and PH associated with pulmonary edema from high altitude sickness.